Acceleron Pharma

Investors/Media

<< Back
Mar 12, 2018

Acceleron to Host Educational Webinar with Leading Clinicians to Provide an Overview of Pulmonary Arterial Hypertension (PAH) and the Sotatercept Phase 2 Trial

- Educational webinar to be held on Wednesday, March 28th at 8:00 a.m. EDT -

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 12, 2018-- Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced that it will host an educational webinar on pulmonary arterial hypertension (PAH) and the Company’s Phase 2 clinical trial of sotatercept in patients with PAH. The webinar will be led by Acceleron’s senior management team and PAH disease experts, Aaron B. Waxman, M.D., Ph.D., and David Badesch, M.D. The webinar is scheduled for Wednesday, March 28, 2018 at 8:00 a.m. EDT.

Dr. Waxman is the director of the Pulmonary Vascular Disease Program at Brigham and Women’s Hospital (BWH). He is also an associate professor of medicine at Harvard Medical School. His clinical interests include PAH, right heart failure, thromboembolic disease and pulmonary vascular disease. He has authored over 110 peer-reviewed publications and has research funding from the National Institutes of Health and the National Heart, Lung, and Blood Institute. Dr. Waxman will present a PAH disease overview and provide an update on the current treatment landscape.

Dr. Badesch is the clinical director of the Pulmonary Hypertension Center at the University of Colorado Hospital. He is also a professor of Divisions of Pulmonary Sciences and Critical Care Medicine and Cardiology at the University of Colorado Anschutz Medical Campus. Dr. Badesch is actively involved in furthering PAH research, treatment options and disease awareness. He has authored over 137 peer-reviewed publications and previously served as the Chair of the Pulmonary Circulation Assembly of the American Thoracic Society, and the Scientific Leadership Council of the Pulmonary Hypertension Association. Dr. Badesch, the Sotatercept Steering Committee Chair, will present the Phase 2 study design.

Webinar Details
Date: Wednesday, March 28, 2018
Time: 8:00 a.m. EDT

Participants can access the live conference call by dialing 877-312-5848 (domestic) or 253-237-1155 (international) and refer to the “Acceleron Sotatercept in PAH Webinar.”

The live webinar can be accessed on the Investors page of the Company's website at www.acceleronpharma.com.

A replay of the webinar will be available approximately two hours after the event on the Acceleron website.

About Sotatercept

Sotatercept is an activin receptor type IIA fusion protein that acts as a ligand trap for members in the transforming growth factor-beta superfamily involved in remodeling a variety of different tissues, including the vasculature and fibrosis. In multiple preclinical studies in PAH, sotatercept decreased vessel muscularization, improved pulmonary arterial pressures, and decreased indicators of right heart failure.

About Pulmonary Arterial Hypertension (PAH)

Pulmonary Arterial Hypertension (PAH) is a rare and chronic, rapidly progressing disorder characterized by the constriction of small pulmonary arteries and elevated blood pressure in the pulmonary circulation. PAH results in significant and progressive strain on the right side of the heart, often leading to limited physical activity, heart failure, and reduced life expectancy. The 5-year survival rate for patients with PAH is approximately 57%. Available therapies generally act by promoting the dilation of pulmonary vessels without addressing the underlying cause of the disease. As a result, PAH often progresses rapidly for many patients despite standard of care treatment. A growing body of research has implicated imbalances in BMP and TGF-beta signaling as a primary driver of PAH in familial, idiopathic and acquired forms of the disease.

About Acceleron

Acceleron is a Cambridge-based, clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. The Company's leadership in the understanding of TGF-beta biology and protein engineering generates innovative compounds that engage the body's ability to regulate cellular growth and repair.

Acceleron focuses its research and development efforts in hematologic, neuromuscular, and pulmonary diseases. In hematology, the Company and its global collaboration partner, Celgene, are developing luspatercept for the treatment of chronic anemia in myelodysplastic syndromes, beta-thalassemia, and myelofibrosis. Acceleron is also advancing its neuromuscular franchise with two distinct Myostatin+ agents, ACE-083 and ACE-2494, and a pulmonary program with a planned Phase 2 trial of sotatercept in pulmonary arterial hypertension.

For more information, please visit www.acceleronpharma.com. Follow Acceleron on Social Media: @AcceleronPharma and LinkedIn.

Source: Acceleron Pharma Inc.

IRC for Acceleron Pharma Inc.
Todd James, 617-649-9393
Vice President, Investor Relations and Corporate Communications
or
Candice Ellis, 617-649-9226
Manager, Investor Relations and Corporate Communications
or
Media:
BMC Communications
Brad Miles, 646-513-3125